logo

Madrigal Pharmaceuticals, Inc. (MDGL)



Trade MDGL now with
  Date
  Headline
8/7/2018 6:57:49 AM Madrigal Pharma Q2 Net Loss $6.46 Mln Or $0.45/Shr Vs Loss $8.35 Mln Or $0.69/Shr Last Year
6/6/2018 11:35:23 PM Madrigal Pharma Prices Public Offering Of 1.35 Mln Shares At $305.00/shr
6/5/2018 4:12:02 PM Madrigal Pharmaceuticals Announces Proposed Public Offering Of Common Stock
5/31/2018 7:13:05 AM Madrigal’s MGL-3196 Achieves Liver Biopsy Endpoints In Patients With NASH At 36 Weeks In Phase 2 Clinical Trial
5/8/2018 6:51:52 AM Madrigal Pharma Q1 Loss Per Share $0.45 Vs Loss $0.50 Last Year
3/13/2018 6:51:54 AM Madrigal Pharma Q4 Loss Per Share $0.67, Flat With Last Year
2/8/2018 6:52:19 AM Madrigal’s MGL-3196 Achieves Primary Endpoint In Patients With Heterozygous Familial Hypercholesterolemia
1/30/2018 7:04:31 AM Madrigal Announces Acceptance Of MGL-3196 Abstract For Main Plenary Presentation At International Liver Congress 2018
12/18/2017 11:37:23 PM Madrigal Pharma Prices Public Offering Of 1.51 Mln Common Stock At $83/Shr